Search Results
Results found for "chronic pain"
- The Real Cost of Strategic Overload in Biotech
Individually, these choices make sense. What did you decide not to pursue to strengthen the main thesis?
- đ° GPCR Weekly News, May 13 to 19, 2024
Dive into this fascinating topic and gain valuable insights from one of the leading experts in the field
- The Moment Biotech Founders Realize the Money Is Gone
The danger is that financial visibility fades while the company keeps moving forward , until choices Each choice makes sense in isolation. đ Together, they quietly reduce flexibility. Infrastructure choices narrow future paths. From a distance, everything still looks manageable. Roadmaps stop being tools for choice and start becoming tools for justification. and partnerships are delayed, not by strategy, but by fear of cash burn 4ïžâŁ Fundraising becomes the main
- High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands
Non-Radioactive Workflow By removing isotopes, researchers gain safer, more scalable, and more environmentally
- Targeting Intracellular Allosteric Sites in GPCRs
Allosteric modulation is gaining prominence in GPCR therapeutics, with the discovery of an intracellular
- From Pipettes to Platforms: The Evolution of GPCR Research
These painstaking manual workflows laid the foundation for what would become the evolution of GPCR research
- GPCR Happy Hour â Boston, Sept 2025
electrophysiology platform, iPSC-derived models, optogenetics, and high-content screening techniques such as cell painting
- Odorant receptors â a bit of smell for drug discovery
In the cardiovascular system, ORs have the potential to operate as the main carriers of endogenously
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
Cy3B label of CELT-419, which fits well for FA and live-cell microscopy measurements, is not the best choice An Order of Magnitude Faster DNA-PAINT Imaging by Optimized Sequence Design and Buffer Conditions.
- Is Your Agonist Really âWorkingââOr Are You Just Seeing What Your System Allows?
think batteries and balance scales), Terry reveals why different tissuesâand even different assaysâcan paint
- Artificial intelligence â faster, smarter, cheaper GPCR drug discovery
The future According to the authors, the future of AI relies in 6 main areas: 1.








